Eliquis is a medicine used to prevent venous thromboembolism (blood clots in the veins) in adults following a hip or knee replacement operation. It is also used in adults to treat deep vein thrombosis (blood clot in a deep vein, usually in the leg) and pulmonary embolism (clot in a blood vessel supplying the lungs), and to prevent their reoccurrence.<\/p>\n
Additionally, Eliquis is used to prevent stroke (caused by blood clots in the brain) and blood clots in other organs in adults with atrial fibrillation (irregular rapid contractions of the upper chambers of the heart). It is used in patients who have one or more risk factors, such as having had a previous stroke, having high blood pressure, diabetes, heart failure or being 75 years old or over.<\/p>\n
Eliquis contains the\u00a0active substance<\/a>\u00a0apixaban.<\/p>\n If apixaban tablets are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj).<\/p>\n Approval Date:\u00a0 2012 If you have a prescription from a Registered Medical Practitioner (RMP),\u00a0IPN<\/a> in Delhi can assist you in obtaining access to genuine medication.\u00a0 Our professional will provide you with a step-by-step guide on how to legally and safely import \u201capixaban tablets\u201d based on the information you provide.<\/p>\nHow can 1 go about obtaining apixaban tablets?<\/h3>\n
ELIQUIS (apixaban) tablets for oral use Initial U.S. Approval: 2012<\/h5>\n
References<\/h3>\n","protected":false},"excerpt":{"rendered":"
apixaban tablets
\nfor oral use Initial U.S. Approval: 2012<\/h2>\nFacts about apixaban tablets<\/h4>\n
\nProprietary Name: On Request
\nActive Ingredient(s): apixaban
\nDosage Forms And Strengths: Tablets: 2.5 mg and 5 mg
\n<\/strong>Company: <\/strong>Bristol Myers Squibb and Pfizer
\nDiseases:<\/strong> Nonvalvular atrial fibrillation, deep vein thrombosis and pulmonary embolism
\nMedicine Approved By: \u2013<\/strong> European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Therapeutic Goods Administration (TGA), Medsafe (NZ)
\nSummary of FDA approved use on approval date:<\/strong> Click Here<\/a>
\n(see Drugs@FDA for complete indication)<\/p>\nAccess the best support services globally<\/h4>\n